LABP-66

LABP-66 is an orally active, systemic small molecule that acts as an agonist of NLRX1 (NLR family member X1), a mitochondria-associated receptor involved in modulating immune responses. By activating the NLRX1 pathway, LABP-66 increases autophagy and oxidative phosphorylation in immune cells while decreasing differentiation of effector CD4+ T cells, reactive oxygen species production, inflammasome formation (including NLRP1 and NLRP3), and inflammatory cytokine production. This mechanism is thought to protect neurons from oxidative stress and reduce central nervous system inflammation. The drug is being developed primarily for neurodegenerative diseases such as multiple sclerosis (MS) and Alzheimer’s disease. Preclinical studies have shown that oral administration of LABP-66 reduces markers of inflammation, neuronal cell stress in the CNS, and disease activity scores in animal models[1][2][3][4][5].